Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Racura Oncology Opens Korean Recruitment for RC220 Phase 1 Solid Tumours Trial
Racura Oncology opens Korea recruitment for RC220 Phase 1 solid tumours trial, expanding to Ewha, Severance and Samsung Medical Center to accelerate enrolment.
Latest Stories — SECTOR DESK
Optiscan Launches US Study of InVue and InForm Imaging Devices for Head and Neck Cancer Surgeries
Optiscan kicks off US Mayo Clinic study of 35-patient InVue/InForm for head and neck cancer; real-time intraoperative imaging aims to back FDA submissions.
Avecho Biotechnology Restarts Final Recruitment Stage for Key Insomnia Trial
Avecho restarts final recruitment for Phase III insomnia trial; 320 more participants to reach 519 after positive interim DMB, de-risked with ~12-month plan.
Austco Healthcare Posts Record FY26 Revenue as Recurring Income Builds
Austco Healthcare posts record FY26 revenue of $94.2m as recurring SMA income grows; strong order book and cash build, flagging upbeat FY27 prospects.
Prescient Therapeutics’ First-in-Class Cancer Drug Approaching a Pivotal Moment
Prescient Therapeutics’ PTX-100 nears pivotal Phase 2a in CTCL; 100% clinical benefit in Phase 1b potential big-pharma partner as first-in-class GGT-1/RAS hit.
Biome Australia Enters Probiotics Market in China with Exclusive H&S Global Deal
Biome Australia secures exclusive China CBEC deal with H&S Global for Activated Probiotics; aims for FY27 launch in US$10.8B market.
Preclinical Data Shows Noxopharm’s Sofra Technology Can Enhance Current Cancer Treatments
Noxopharm's Sofra preclinical data show immune activation with dying cancer cells, hinting Sofra can boost standard cancer therapies.
Integral Diagnostics Lifts FY26 Earnings as Capitol Synergies Beat Expectations
Integral Diagnostics FY26 revenue up 25.6% to A$788.7m; NPAT up 50% to A$47.4m as Capitol synergies beat; final dividend 6.0c; margins lift.
Island Pharmaceuticals Builds Galidesivir Inventory for Outbreak Response
Island Pharmaceuticals expands Galidesivir stock with a second GMP campaign, targeting 700-800 treatment courses by Q4 2026 as Bundibugyo Ebola spreads; MEURI.
Medical Developments International Builds Penthrox Momentum on Improved Cash Flow
Medical Developments International ups FY26 revenue 9% to $42.6m; Penthrox demand boosts cash flow; paediatric approval expands UK/Europe use, driving momentum.
Recce Pharmaceuticals Expands Phase 3 Diabetic Foot Trial With Comparator Arm
Recce expands Phase 3 diabetic foot infection trial with R327G active comparator arm, pursuing non-inferiority vs antibiotics; interim data after 104 patients.
Entropy Neurodynamics Appoints BioCina for Global Manufacture of TRP-8803 IV Psilocin
Entropy Neurodynamics appoints BioCina for global manufacture of TRP-8803 IV psilocin, enabling regulatory submissions and rapid scale-up across indications.